GoodRx: Losing Relevance With Consumers (Downgrade)

Gary Alexander33.45K FollowersFollow5ShareSavePlay(10min)CommentsSummaryGoodRx faces intensifying headwinds, including customer attrition, revenue decline, and disruptive competition from TrumpRx.I downgrade GDRX to "Sell," citing deteriorating fundamentals, a shrinking customer base, and a challenged business model.Despite trading at 4.3x EV/FY26 adjusted EBITDA, GDRX's category appears in secular decline with limited acquisition appeal.Net debt and declining EBITDA (-15% y/y at minimum guidance) amplify risks as revenue is forecast to fall 2% to 6% in FY26. Dmitry Vorobyev/iStock via Getty Images There's absolutely no doubt that 2026 has been an incredibly punishing stock market to invest in. Investors have had to contend with a wide array of negative catalysts, ranging from AI "SaaSpocalypse" fears to the rising geopolitical conflict in the Middle East that isThis article was written byGary Alexander33.45K FollowersFollowWith combined experience of covering technology companies on Wall Street and working in Silicon Valley, and serving as an outside adviser to several seed-round startups, Gary Alexander has exposure to many of the themes shaping the industry today. He has been a regular contributor on Seeking Alpha since 2017. He has been quoted in many web publications and his articles are syndicated to company pages in popular trading apps like Robinhood.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.